On February 14, 2023 enGene Inc., a clinical-stage biotechnology company pioneering non-viral gene therapies for local administration to mucosal tissues enabled by its proprietary DDX platform, reported a poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium being held from February 16th to 18th, 2023 (Press release, enGene, FEB 14, 2023, View Source [SID1234627216]). The poster will highlight positive pharmacodynamic urinary biomarker data, an encouraging safety profile across all tested doses, and strong preliminary efficacy data based on cytology, cystoscopy, and biopsy, including a 3-month complete response rate of 71%.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presenter, Dr. Gary Steinberg MD, Professor at the Perlmutter Cancer Center and Department of Urology and Director of the Goldstein Urology Bladder Cancer Program of NYU Langone Health, said: "While the data are still early, EG-70’s safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive Carcinoma in situ (CIS)." He added, "If these trends continue into Phase II, I am optimistic that EG-70 will become an important, useful, and innovative tool in the fight against non-muscle invasive bladder cancer (NMIBC), especially given its non-viral nature and relative ease of handling and use."
"From the start, we designed EG-70 to be a safe, practical, and effective option for both patients and physicians that will integrate seamlessly into community urology clinics," said Jason Hanson, CEO of enGene. "It is deeply rewarding to see EG-70 continuing its best-in-class trajectory, and we look forward to the upcoming initiation of the pivotal Phase II portion of the LEGEND study."
Presentation highlights:
71% CR rate at 3 months and a rate of patients continuing past 3 months of 82%, both based on a total of 17 patients.
A strong safety profile, with observed adverse events largely consistent with urinary tract instrumentation used to deliver EG-70.
Dose-responsive induction of the IL-12 therapeutic transgene expression, as measured in urine.
Poster session details:
Title: Clinical results of a Phase 1 study of intravesical EG-70 in patients with BCG-unresponsive NMIBC
Abstract Number: 512
Session Information: Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: Friday, February 17, 2023, 3:30PM ET
Presenter: Gary Steinberg, M.D.
Additional meeting information and the published abstract are available on the ASCO (Free ASCO Whitepaper) GU website (View Source).
About EG-70
Based on enGene’s DDX platform, EG-70 is a novel non-viral gene therapy encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system. By stimulating both arms of the immune system, intravesically administered EG-70 yields remarkable tumor regression in preclinical models of bladder cancer, with induction of effective immunological memory and minimal signs of toxicity.
About the LEGEND study
The LEGEND study, both first-in-human and first-in-class, is an open-label, monotherapy, multi-center, dose-escalation trial evaluating safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of EG-70 administered by intravesical instillation. To learn more about the first-in-human clinical trial of EG-70 in BCG-unresponsive NMIBC, please visit ClinicalTrials.gov. For additional information about the LEGEND study, please visit thelegendstudy.com.